6 results on '"Islam Bolad"'
Search Results
2. Stent-Only Versus Adjunctive Balloon Angioplasty Approach for Saphenous Vein Graft Percutaneous Coronary Intervention
- Author
-
Kreton Mavromatis, Emmanouil S. Brilakis, Islam Bolad, Robert Edson, Edward O. McFalls, Kendrick A. Shunk, Mei Chiung Shih, Faisal Latif, Subhash Banerjee, Kul Aggarwal, Lauren Uyeda, Barry F. Uretsky, Huu Tam Truong, Anand Irimpen, Steven Goldman, Bavana V. Rangan, Deepak L. Bhatt, David R. Holmes, Sunil V. Rao, Vasilios Papademetriou, Khaled M. Ziada, Raghava S. Velagaleti, and Scott Kinlay
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,medicine.medical_treatment ,Distal embolization ,Saphenous vein graft ,Myocardial Infarction ,Balloon ,Article ,Double-Blind Method ,Risk Factors ,Angioplasty ,medicine ,Humans ,Direct stenting ,Saphenous Vein ,Prospective Studies ,cardiovascular diseases ,Myocardial infarction ,Angioplasty, Balloon, Coronary ,Coronary Artery Bypass ,Vascular Patency ,Aged ,business.industry ,Coronary Thrombosis ,Graft Occlusion, Vascular ,Percutaneous coronary intervention ,Stent ,Middle Aged ,medicine.disease ,United States ,Surgery ,Treatment Outcome ,surgical procedures, operative ,Female ,Stents ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background: Direct stenting without pre-dilation or post-dilation has been advocated for saphenous vein graft percutaneous coronary intervention to decrease the incidence of distal embolization, periprocedural myocardial infarction, and target lesion revascularization. Methods: We performed a post hoc analysis of patients enrolled in the DIVA (Drug-Eluting Stents Versus Bare Metal Stents in Saphenous Vein Graft Angioplasty; NCT 01121224) prospective, double-blind, randomized controlled trial. Patients were stratified into stent-only and balloon-stent groups. Primary end point was 12-month incidence of target vessel failure (defined as the composite of cardiac death, target vessel myocardial infarction, or target vessel revascularization). Secondary end points included all-cause death, stent thrombosis, myocardial infarction, and target lesion revascularization during follow-up. Results: Of the 575 patients included in this substudy, 185 (32%) patients underwent stent-only percutaneous coronary intervention. Patients in the stent-only versus balloon-stent group had similar baseline characteristics and similar incidence of target vessel failure at 12-months (15% versus 19%; hazard ratio, 1.34 [95% CI, 0.86–2.08]; P =0.19). During long-term follow-up (median of 2.7 years), the incidence of definite stent thrombosis (1% versus 5%; hazard ratio, 9.20 [95% CI, 1.23–68.92]; P =0.0085), the composite of definite or probable stent thrombosis (5% versus 11%; hazard ratio, 2.52 [95% CI, 1.23–5.18]; P =0.009), and target vessel myocardial infarction (8% versus 14%; hazard ratio, 1.92 [95% CI, 1.08–3.40]; P =0.023) was lower in the stent-only group. Multivariable analysis showed that a higher number of years since coronary artery bypass grafting and >1 target saphenous vein graft lesions were associated with increased target vessel failure during entire follow-up, while preintervention Thrombolysis in Myocardial Infarction-3 flow was protective. Conclusions: In patients undergoing percutaneous coronary intervention of de novo saphenous vein graft lesions, there was no difference in target vessel failure at 12 months and long-term follow-up in the stent-only versus the balloon-stent group; however, the incidence of stent thrombosis was lower in the stent-only group, as was target vessel myocardial infarction. Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT 01121224.
- Published
- 2020
3. Endothelial dysfunction: its role in hypertensive coronary disease
- Author
-
Islam Bolad and Patrice Delafontaine
- Subjects
medicine.medical_specialty ,Endothelium ,Coronary Disease ,Arginine ,Nitric Oxide ,Article ,Coronary artery disease ,chemistry.chemical_compound ,Insulin resistance ,Internal medicine ,Hydroxyeicosatetraenoic Acids ,Humans ,Medicine ,Endothelial dysfunction ,Antihypertensive Agents ,business.industry ,Angiotensin II ,Oxidants ,medicine.disease ,Hyperaldosteronism ,Blood pressure ,medicine.anatomical_structure ,chemistry ,Hypertension ,Cardiology ,Endothelium, Vascular ,Cardiology and Cardiovascular Medicine ,business ,Asymmetric dimethylarginine ,Kidney disease - Abstract
Purpose of review Coronary artery disease is the major cause of death worldwide. Hypertension is a major risk factor for developing coronary disease. It is now recognized that endothelial dysfunction is an early marker of coronary artery disease before structural changes to the vessel wall are apparent on angiography or intravascular ultrasound and that it has a prognostic value in predicting cardiovascular events in hypertensive patients. This review addresses recent developments in hypertension-induced endothelial dysfunction. Recent findings Hyperaldosteronism causes endothelial dysfunction independent of high blood pressure. Exaggerated exercise blood pressure response has been related to endothelial dysfunction. Cyclosporin-A-induced endothelial dysfunction is related to reduced cholesterol content in caveolae. Chronic kidney disease induces changes in caveoli-1 and thus contributes to the reduced nitric oxide bioavailability, and causes oxidative stress independent of the high blood pressure. Asymmetric dimethylarginine plays a role in endothelial dysfunction in hypertensive patients independent of insulin resistance. 20-Hydroxyeicosatetraenoic acid is an independent predictor of hypertension in postmenopausal women. Endothelial dysfunction precedes and predicts the development of hypertension in postmenopausal women. Oral treatment with L-arginine improves endothelial dysfunction in hypertensives and lowers the blood pressure. Summary The pathophysiology of endothelial dysfunction in hypertension is multifactorial. Recent findings have contributed to our understanding of mechanisms of endothelial dysfunction and support a role for early intervention to prevent irreversible vascular and organ damage.
- Published
- 2005
4. Percutaneous treatment of superior vena cava obstruction following transvenous device implantation
- Author
-
Roy M. John, David Martin, Islam Bolad, Dilip Mathew, Thomas C. Piemonte, and Sree Karanam
- Subjects
Adult ,Male ,Pacemaker, Artificial ,Superior Vena Cava Syndrome ,medicine.medical_specialty ,Time Factors ,Percutaneous ,medicine.medical_treatment ,Superior vena cava ,Angioplasty ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Device Removal ,Aged ,Retrospective Studies ,business.industry ,Retrospective cohort study ,Phlebography ,General Medicine ,Middle Aged ,Implantable cardioverter-defibrillator ,Defibrillators, Implantable ,Surgery ,Catheter ,Female ,Implant ,Radiology ,Tomography, X-Ray Computed ,Cardiology and Cardiovascular Medicine ,Complication ,business ,Follow-Up Studies - Abstract
The aim of this study is to assess the feasibility and safety of percutaneous treatment of superior vena cava (SVC) obstruction following transvenous device implantation. SVC obstruction is an uncommon but serious complication that can occur following permanent pacemaker or cardioverter defibrillator implantation utilizing transvenous endocardial leads. The treatment has traditionally been surgical but with the advent of stents, percutaneous approach is becoming popular. We report on the prevalence of SVC obstruction and the safety of its percutaneous catheter-based treatment. This is a retrospective study of SVC obstruction following device implantation in our institution from January 1993 through November 2003. A total of 1,850 permanent pacemaker and 1,200 implantable cardioverter defibrillator initial implants were performed during that period. Three patients developed SVC obstruction following implant (prevalence, 1/1,000 implant). Two patients were males and the mean age at implant was 57 ± 13 years. Laser lead extraction and SVC angioplasty with or without stenting were performed in all patients. In two of them, this was followed by reimplantation of new systems. There were no procedural complications or mortality. The patients remain free of SVC obstruction symptoms 24 ± 19 months after treatment. SVC obstruction prevalence after device implantation is low. Percutaneous treatment of SVC obstruction can be safely performed and appears to be effective in maintaining medium-term patency. © 2005 Wiley-Liss, Inc.
- Published
- 2005
5. Effectiveness of early implantation of cardioverter defibrillator for postoperative ventricular tachyarrhythmia
- Author
-
Richard S. D’Agostino, David Martin, Gregory F. Michaud, Sree Karanam, Islam Bolad, David M. Shahian, Roy M. John, Carolyne MacLellan, and Florence Parrella
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,Ventricular Tachyarrhythmias ,Early Recurrence ,Defibrillation ,medicine.medical_treatment ,Risk Assessment ,Severity of Illness Index ,Cardioverter-Defibrillator ,Electrocardiography ,Postoperative Complications ,Internal medicine ,medicine ,Humans ,Cardiac Surgical Procedures ,Aged ,Probability ,Retrospective Studies ,business.industry ,Retrospective cohort study ,Middle Aged ,Survival Analysis ,Defibrillators, Implantable ,Surgery ,Cardiac surgery ,Patient population ,Treatment Outcome ,Tachycardia, Ventricular ,cardiovascular system ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business ,Follow-Up Studies - Abstract
The effectiveness of implantable cardioverter defibrillators (ICDs) implanted in the early postoperative period after cardiac surgery for ventricular tachyarrhythmias is unknown, because all of the major trials excluded this patient population. Thus, a 10-year retrospective study was conducted of patients who had ICDs implanted for de novo postoperative ventricular tachyarrhythmias during the index admission for cardiac surgery. There was a high rate of early recurrence of ventricular tachyarrhythmia treated by defibrillators, and this finding questions the exclusion of this important patient population from large trials.
- Published
- 2004
6. Have all the ICD primary prevention trials excluded an important group of patients?
- Author
-
Islam Bolad and David Martin
- Subjects
medicine.medical_specialty ,business.industry ,Ventricular Tachyarrhythmias ,Patient Selection ,medicine.medical_treatment ,Perioperative ,Revascularization ,Implantable cardioverter-defibrillator ,Icd therapy ,Perioperative Care ,Defibrillators, Implantable ,Patient population ,Increased risk ,Physiology (medical) ,Primary prevention ,Myocardial Revascularization ,Ventricular Dysfunction ,cardiovascular system ,medicine ,Humans ,cardiovascular diseases ,Cardiology and Cardiovascular Medicine ,Intensive care medicine ,business - Abstract
Primary prevention trials of implantable cardioverter defibrillator (ICD) therapy have generally excluded patients early after revascularization. Clinicians are commonly faced with patients who have ventricular dysfunction and nonsustained ventricular tachyarrhythmia developing shortly after revascularization. Since there are no evidence-based guidelines, management is currently at the discretion of the treating clinician. Recently, evidence has emerged that this patient population is at increased risk of development of life-threatening ventricular tachyarrhythmia and, pending prospective trials, we suggest that ICD therapy should be used in appropriately selected patients with perioperative ventricular arrhythmia.
- Published
- 2005
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.